Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature.
about
Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule.Rationale of using different biological therapies in rheumatoid arthritis.Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy.Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions.Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to knowTreatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management.Maternal death following cardiopulmonary collapse after delivery: amniotic fluid embolism or septic shock due to intrauterine infection?Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register.Placental TNF-α signaling in illness-induced complications of pregnancy.Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use.Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.Two case reports of generalized pustular psoriasis of pregnancy: Different outcomesSafety of Tumor Necrosis Factor Inhibitors during Pregnancy and Breastfeeding.Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis.Novel TNF antagonists for the treatment of rheumatoid arthritis.A safety assessment of tumor necrosis factor antagonists during pregnancy.Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies.Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease.Biological therapies for psoriasis.Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients.Therapy of complicated Crohn's disease during pregnancy--an interdisciplinary challenge.Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy.Psoriasis during pregnancy: characteristics and important management recommendations.Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments.Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series.Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review.Successful childbearing in two women with rheumatoid arthritis and a history of miscarriage after etanercept treatment.Detrimental roles of TNF-alpha in the antiphospholipid syndrome and de novo synthesis of antiphospholipid antibodies induced by biopharmaceuticals against TNF-alpha.Effect of Etanercept on the Success of Assisted Reproductive Technology in Patients with Endometrioma.[Anticytokine therapy].
P2860
Q33623762-82EF8891-1DF5-4A71-9316-A5DBA3AD52A4Q34153073-DA113A3B-1F5E-489F-99A3-CA6D726CB0CFQ34333931-02CCDBAA-DC21-4487-8D5C-121EA5C0680FQ34385326-623C89F5-8400-445D-8AA3-2CCC2B629ADCQ34389362-1B45CC57-E1B0-4608-8B29-50523F5805B6Q34476952-49BF931B-12F9-4A6C-AD8E-94C81023516BQ34494722-43FCFF45-7045-440C-ABAF-51F0FAC87A9BQ34758793-22BBA000-844D-49F3-88F2-BF74EF9CFC04Q35071279-21B2CFFC-9016-4B09-AABA-CE6261A677DCQ35415687-E115220D-49C2-4609-BCF5-16F9552D50DBQ36819564-D801AA97-A83C-4315-AD25-E9460725E8CDQ37107287-9A45B060-3C0C-4274-B712-AAE4971134F7Q37149381-3BC7610A-06CB-4839-AE2D-623771D04DF8Q37616969-6859A47C-FE37-482C-B4FB-6388EAB626AEQ37650386-5DF9BE01-F13F-463C-89B6-CD280016625BQ37724349-ED3AFD2D-A610-4ED7-BDB2-C8E3C18C1B43Q37980484-0A132800-E4F3-4316-BB49-2C1C768B3A58Q38099248-668754FF-24EB-47A3-ADF6-BCF3E8590A3AQ38113455-38924E82-9C48-4C2D-B422-0C28FE43196CQ38155648-F8674673-3C14-4B59-AFF8-4E6EA5FC1E0BQ38205869-0C0F90F8-89E2-4584-8223-D306DFC3DE62Q38209086-BB10135B-A78C-4D92-B115-DB66365D3448Q38269243-0699C13E-822D-4B22-8994-28B9D9DE1488Q38420877-6C582B10-593F-4EF5-839D-3007CDC7B58EQ38543325-DB4353DE-8BCA-4C2C-B0FF-12AB5C18376DQ39029592-10586CD8-0793-4C30-BD2B-284FD2A1E322Q39039141-29D716BC-0E86-4FE5-BCD0-FAF7E5FEA7C6Q46164980-EAD73061-111E-48BE-B0B1-1107C35C21BDQ48192268-B7647A8A-A582-4E2A-BD7D-FE92485CB1A4Q50058281-93FBF05F-06EB-4C7C-B8FF-17D206726EC4Q52884662-72BF2295-4DD0-4C1D-901E-7AAEF9004447
P2860
Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Exposition to anti-TNF drugs d ...... and review of the literature.
@en
Exposition to anti-TNF drugs d ...... and review of the literature.
@nl
type
label
Exposition to anti-TNF drugs d ...... and review of the literature.
@en
Exposition to anti-TNF drugs d ...... and review of the literature.
@nl
prefLabel
Exposition to anti-TNF drugs d ...... and review of the literature.
@en
Exposition to anti-TNF drugs d ...... and review of the literature.
@nl
P2093
P50
P1433
P1476
Exposition to anti-TNF drugs d ...... and review of the literature.
@en
P2093
Antoine Martin
Béatrice Pallot-Prades
CRI (Club Rhumatismes et Inflammation)
Elisabeth Solau-Gervais
Isabelle Azaïs
Michel De Bandt
Philippe Goupille
Xavier Mariette
Yves Maugars
P356
10.1016/J.JBSPIN.2008.04.016
P577
2008-12-06T00:00:00Z